Leerink upgraded Amylyx (AMLX) to Outperform from Market Perform with a $10 price target
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMLX:
- Amylyx doses first participant in Phase 3 LUCIDITY trial of avexitide
- Biotech Alert: Searches spiking for these stocks today
- Amylyx doses first participant in LUMINA trial
- Amylyx upgraded to Outperform from Neutral at Mizuho
- Cautious Hold Rating for Amylyx Pharmaceuticals Amid Key Clinical Updates and Stable Financial Position